Under the provisions of the conditional approval, Janssen commits to support a Phase 3 study to further substantiate the benefit-risk for SIRTURO^® and define its optimal use.

If approved, bedaquiline could be one of the first drugs with a new mechanism of action for TB in more than 40 years and one of the first ever to be specifically indicated for MDR-TB.